CRISPR Therapeutics - CRSP Stock Forecast, Price & News

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Needham & Company LLC reduced their target price on CRISPR Therapeutics from $170.00 to $122.00 in a report on Friday, May 13th. BMO Capital Markets began coverage on CRISPR Therapeutics in a research note on Thursday, June 16th. They set an "outperform" rating and a $98.00 price target for the company. Piper Sandler lifted their price target on CRISPR Therapeutics from $115.00 to $121.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 22nd. Royal Bank of Canada dropped their price objective on CRISPR Therapeutics from $95.00 to $85.00 in a research report on Tuesday, May 10th. Finally, The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $52.00 to $46.00 and set a "neutral" rating for the company in a research report on Tuesday, May 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $116.19.

CRISPR Therapeutics Stock Up 3.2 %

Shares of CRISPR Therapeutics stock opened at $81.40 on Friday. The business has a fifty day simple moving average of $70.64 and a 200 day simple moving average of $63.09. The stock has a market cap of $6.31 billion, a PE ratio of 22.55 and a beta of 1.93. CRISPR Therapeutics has a 12 month low of $42.51 and a 12 month high of $142.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported ($2.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.91) by ($0.41). CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. During the same period last year, the firm earned ($1.51) EPS. CRISPR Therapeutics's quarterly revenue was up 74.4% compared to the same quarter last year. Analysts expect that CRISPR Therapeutics will post -8.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 25,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $75.91, for a total value of $1,897,750.00. Following the completion of the transaction, the chief executive officer now directly owns 290,279 shares in the company, valued at approximately $22,035,078.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.70% of the company's stock.